Mathematical Modelling of a Hypoxia-regulated Oncolytic Virus Delivered by Tumour-associated Macrophages

Publication date: Available online 23 October 2018Source: Journal of Theoretical BiologyAuthor(s): Michael A. Boemo, Helen M. ByrneAbstractTumour hypoxia has long presented a challenge for cancer therapy: Poor vascularisation in hypoxic regions hinders both the delivery of chemotherapeutic agents and the response to radiotherapy, and hypoxic cancer cells that survive treatment can trigger tumour regrowth after treatment has ended. Tumour-associated macrophages are attractive vehicles for drug delivery because they localise in hypoxic areas of the tumour. In this paper, we derive a mathematical model for the infiltration of an in vitro tumour spheroid by macrophages that have been engineered to release an oncolytic adenovirus under hypoxic conditions. We use this model to predict the efficacy of treatment schedules in which radiotherapy and the engineered macrophages are given in combination. Our work suggests that engineered macrophages should be introduced immediately after radiotherapy for maximum treatment efficacy. Our model provides a framework that may guide future experiments to determine how multiple rounds of radiotherapy and macrophage virotherapy should be coordinated to maximise therapeutic responses.
Source: Journal of Theoretical Biology - Category: Biology Source Type: research

Related Links:

Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL Abstract Ovarian cancer is often termed a silent killer due to the late onset of symptoms. Whilst patients initially respond to chemotherapy, they rapidly develop chemo-resistance. Oncolytic adenoviruses (OAds) are promising anti-cancer agents engineered to "hijack" the unique molecular machinery of cancer cells enabling tumour-selective viral replication. This allows spread to adjacent cells and amplification of oncolysis within the tumour. OAds represent an excellent opportunity for ovarian cancer therapy via intra-pe...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS:  Oncolytic Ad5NULL-A20 virotherapies represent an excellent vector for local and systemic targeting of αvβ6-over-expressing cancers, and exciting platforms for tumour selective over-expression of therapeutic anti-cancer modalities, including immune checkpoint inhibitors. PMID: 29798908 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 5 November 2016 Source:Japanese Dental Science Review Author(s): Yoshiaki Yura A virus is a pathogenic organism that causes a number of infectious diseases in humans. The oral cavity is the site at which viruses enter and are excreted from the human body. Herpes simplex virus type 1 (HSV-1) produces the primary infectious disease, gingivostomatitis, and recurrent disease, labial herpes. HSV-1 is one of the most extensively investigated viruses used for cancer therapy. In principle, HSV-1 infects epithelial cells and neuronal cells and exhibits cytotoxicity due to its cytopathic effects o...
Source: Japanese Dental Science Review - Category: Dentistry Source Type: research
Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy ...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget. 2016 Apr 1; Authors: Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL Abstract Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell types. However, effective clinical applications are hindered by poor tumor-selectivity and vector neutralization. We generat...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
An ultimate goal of the developers of cancer genetherapy/virotherapy is to develop a device enabling systemic treatment of the patients with advanced or spread diseases. The targeting at the level of infection, which can define the initial distribution following intravenous administration, is considered to be the most important for realization of systemic therapy. Adenovirus which has very high in vivo transduction efficiency is an attractive vector for designing novel cancer therapeutics for systemic therapy, and we and others have been working on this issue in the field of oncolytic adenovirus (OAd). However, the success...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
This article reviews recent highlights in the rapidly evolving field of multidisciplinary therapy with telomelysin.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Emerging evidence indicates that host immunity is critical for successful cancer virotherapy. We found that oncolytic adenovirus Delta-24-RGD elicited antiglioma immunity in an immunocompetent murine model. Recent studies suggested that the therapeutic efficacy of immune checkpoint blockade in cancer patients could be enhanced by strategies inducing tumor inflammation. We hypothesized that highly immunogenic adenovirus combined with targeting immune co-stimulator would result in better anti-tumor efficiency. Thus, we used the backbone of Delta-24-RGD to express the mouse OX40 ligand to increase the recognition of tumor-ass...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Immunology Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Cancer Therapy Source Type: research
More News: Adenoviruses | Biology | Cancer | Cancer & Oncology | Cancer Therapy | Virotherapy